Subscribe to Updates in Healthcare

RSS By Email

RSS By RSS

Add to Google Reader or Homepage

Subscribe in Bloglines


The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.Learn more about GLG's Compliance Framework


This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
Find Out More

All GLG News Analyses Filed Under: Endocrinology

Articles with lock require a GLG News subscription
Posted April 7, 2008
Taranabant--To Be or Not To Be
Analysis of: Taranabant looks promising | www.taranabant-health.com
Author: GLG Member Program Contributor
Although the concept is exciting--an inverse agonist at the cannabinoid-1 (CB-1) receptor to reduce appetite, this medicine has a lot of bad press from rimonabant to overcome.  The major problem with rimonabant was psychopathological reactions in patients.  We do not yet know whether this...
Posted April 7, 2008
Good Prospect- but how much will it cost?
Analysis of: Amgen Drug Helps Bones | online.wsj.com
Author: GLG Member Program Contributor
We indeed better meds for the treatment of osteoporosis. If it indeed shows fracture reduction besides increased bone density with few side effects it will have a place in the market.The other issue, however, will be the cost and which insurers will cover it now that we have generic fosomax.
Posted April 7, 2008
Taranabant Drections: To Success or to Failure?
Analysis of: Taranabant looks promising | www.taranabant-health.com
Author: GLG Member Program Contributor
The article shows that Taranabant is promising anti-obesity drug that may have better luck with the FDA than Rimonabant. Although the trial results are excellent, the company removed higher doses from future trials! What we should learn from Rimonabant failure and Exenatide success?
Posted April 7, 2008
Taranabant directions: To gain or to Failure
Analysis of: Phase III Data Showed Taranabant, Merck's Investigational Medicine to Treat Obesity, Led to Statistically Significant Weight Loss | pharmalive.com
Author: GLG Member Program Contributor
The market is hungry for a weight loss drug with diabetes benefit. Currently, the FAD has phobia of the SEs with new drugs in this category Failure of Rimonabant was due to wrong direction of Sanofi Aventis in their approach to the FDA Taranabant may have better luck, especially if Merck take...
Posted April 7, 2008
Still too early to tell
Analysis of: Phase III Data Showed Taranabant, Merck's Investigational Medicine to Treat Obesity, Led to Statistically Significant Weight Loss | pharmalive.com
Author: GLG Member Program Contributor
This drug also has a significant side effect profile related to pyschiatric issues. Similar drugs have not come to the market because of this.
Posted April 4, 2008
Good news for Obesity - Taranabant shows significant weight loss
Analysis of: Phase III Data Showed Taranabant, Merck's Investigational Medicine to Treat Obesity, Led to Statistically Significant Weight Loss | pharmalive.com
Author: GLG Member Program Contributor
This article has reported Merck's successful clinical trial to obtain significant efficacy for Taranabant, an investigational medicine to treat Obesity. The news is particularly important for showing a longitudinal effect in the clinical significance for Taranabant, and a prospective market for...
Posted April 4, 2008
Supplements Proactive
Analysis of: New Data Showed Actos (pioglitazone HCl) Prevented Progression of Atherosclerotic Plaque Volume in Patients With Type 2 Diabetes | pharmalive.com
Author: GLG Member Program Contributor
This study should give more confidence for the use of the drug.
Posted March 28, 2008
Too much of a "good' thing
Analysis of: Another Bad Break For Merck? | www.pharmalot.com
Author: GLG Member Program Contributor
It is unclear how long bisphosphonates should be given. These findings suggest,if confirmed, that a limit should be placed.
Joseph Bass Posted March 28, 2008
Another Glinide: Where's the Beef?
Analysis of: Elixir Announces Completion of Enrollment in Pivotal Phase III Clinical Trial for New Diabetes Drug | www.pipelinereview.com
Author: Joseph Bass, Division Head of Endocrinology and Metabolism Evanston Northwestern Healthcare
Elixir has turned to a strategy devoid of innovation by selecting a combination glinide (metiglinide) plus glucophage for treatment of type 2 diabetes.  With the new availability of DPP4 inhibitors (sitagliptin/alogliptin) and incretin agonists (eg byetta), what is the prospect of another K channel...
Posted February 26, 2008
Possibly more ways of fighting against glucocorticoid related osteoporesis
Analysis of: FORSTEO(R) Receives Positive Opinion from the European Committee for Medicinal Products for Human Use for the Treatment of Glucocorticoid-Induced Osteoporosis | www.pipelinereview.com
Author: GLG Member Program Contributor
Glucocorticoid-induced osteoporosis has been major problems for the people who use long-term steroid.
Previous Page : 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 Next71 to 80 of 373

More GLG News in
Healthcare

Most Popular:
Source Article | Expert Analyses
 

GLG News: What Experts Think Is Important





Analytics


Generated at 2008-12-05T05:45:18.353